EMBC Embecta (EMBC) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001872789
Cluster · 4 insidersC-suite buying · 3Form 144 · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
143
13F, latest reported quarter
What the filings say about EMBC
Insiders, 180 days
+$521.0K net bought
4 buyers · 1 seller · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$36.9K
1 notice
Embecta insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Embecta Corp. insiders bought a net $521.0K of stock across 14 Form 4 purchases and sales, with 4 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 13, 2025.
- The trade is 11.7% of the 53,828 shares held after it.
- No other insider sold within 30 days.
- 143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Morris Milton Mayo sold about $37.0K of EMBC on Sep 4, 2026, the largest insider sale at the company since 2025; 143 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 41.1% of the 109,587 shares held after it.
- 3 other insiders bought within 30 days.
- 143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director HOMBACH ROBERT J. bought about $223.8K of EMBC on Aug 12, 2026, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 143 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 10, 2023.
- The trade is 7.6% of the 262,915 shares held after it.
- 3 other insiders bought within 30 days.
- 143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Pres, Pharm Svc&Prod Mgmt, CLO Mann Jeffrey Z bought about $99.8K of EMBC on Aug 12, 2026, the largest insider purchase at the company since 2025; 3 other insiders bought within 30 days and 143 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 10, 2023.
- The trade is 6.5% of the 309,138 shares held after it.
- 3 other insiders bought within 30 days.
- 143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP and CFO Elguicze Jacob bought about $93.4K of EMBC on Aug 12, 2026, the largest insider purchase at the company since 2025; 3 other insiders bought within 30 days and 143 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Aug 10, 2023.
- The trade is 3.7% of the 804,918 shares held after it.
- 3 other insiders bought within 30 days.
- 143 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Kurdikar Devdatt bought about $140.9K of EMBC on Aug 12, 2026, the largest insider purchase at the company since 2025; 3 other insiders bought within 30 days and 143 funds added in the latest 13F quarter.14 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$521.0K over 180 days
+$521.0K over 90 days
more than 87% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
143 funds bought in last quarter
more than 74% of Medical Devices
Revenue
-3.8% year over year
below 82% of Medical Devices
Margin
8.8% net margin
more than 80% of Medical Devices
Buybacks
$8.7M repurchased, FY to 2026-06-30
below 66% of Medical Devices
Short interest
10.7% of the float short (float per yahoo 2026-10-27) · 6.2 days to cover · settled 2026-10-15
more than 89% of Medical Devices
The situation: each line is one rule over one dataset
4 insiders bought a net $521.0K while the stock fell 26% over six months, but 1 Form 144 notice ($36.9K) are queued to sell.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch EMBC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-50.4%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EMBC: institutional holders (13F)
13F holdings, latest reported quarter
4,599,771 sh
$15.0M
4,315,952 sh
$14.1M
2,557,148 sh
$8.3M
2,534,961 sh
$8.3M
2,355,117 sh
$7.7M
Congress trades in EMBC
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
EMBC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
Morris Milton Mayo
Filed 2026-09-04
$36.9K
EMBC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Royce Quant Small-Cap Quality Value ETF
$141.2K position · as of 2026-06-30
0.5%
Columbia Small Cap Value Discovery Fund
$5.0M position · as of 2026-07-31
0.2%
Harbor AlphaEdge Small Cap Earners ETF
$23.4K position · as of 2026-07-31
0.2%
Columbia Variable Portfolio - Small Cap Value Discovery Fund
$803.4K position · as of 2026-06-30
0.2%
AMG Yacktman Fund
$11.4M position · as of 2026-06-30
0.2%
MFS Blended Research Small Cap Equity Fund
$507.1K position · as of 2026-05-31
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. Kurdikar
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$7.5M
-$1.3M
$1.8M
-49%
-31%
2022
$11.3M
$11.1M
$2.6M
-5%
-20%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
4 insiders reported buying shares.
The record shows a net $521.0K bought by insiders over 180 days, 143 funds added last quarter, $36.9K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
EMBC financials
Revenue growth
-3.8%
XBRL, annual
Net margin
8.8%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM EMBC
| FY Sep 2025 | $1.1B |
| FY Sep 2024 | $1.1B |
| FY Sep 2023 | $1.1B |
| FY Sep 2022 | $1.1B |
| FY Sep 2021 | $1.2B |
| Jun 2026 | $271.7M |
| Mar 2026 | $221.8M |
| Dec 2025 | $261.2M |
| Sep 2025 | $264.0M |
| Jun 2025 | $295.5M |
| Mar 2025 | $259.0M |
| Dec 2024 | $261.9M |
| Sep 2024 | $286.1M |
At each fiscal year end
Single quarter
Net margin, TTM
+8.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM EMBC
| FY Sep 2025 | +8.8% |
| FY Sep 2024 | +7.0% |
| FY Sep 2023 | +6.3% |
| FY Sep 2022 | +19.8% |
| FY Sep 2021 | +35.6% |
| Jun 2026 | +7.8% |
| Mar 2026 | -1.8% |
| Dec 2025 | +16.9% |
| Sep 2025 | +10.0% |
| Jun 2025 | +15.4% |
| Mar 2025 | +9.1% |
| Dec 2024 | +0.0% |
| Sep 2024 | +5.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$164.6M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM EMBC
| FY Sep 2025 | $182.4M |
| FY Sep 2024 | $19.9M |
| FY Sep 2023 | $41.2M |
| FY Sep 2022 | $388.6M |
| FY Sep 2021 | $419.5M |
| Jun 2026 | $40.7M |
| Mar 2026 | $30.6M |
| Dec 2025 | $16.6M |
| Sep 2025 | $76.7M |
| Jun 2025 | $80.8M |
| Mar 2025 | $31.7M |
| Dec 2024 | -$6.8M |
| Sep 2024 | $26.6M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity EMBC
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | 0.00x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.12x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt EMBC
| FY Sep 2025 | 0.14x |
| FY Sep 2024 | 0.02x |
| FY Sep 2023 | 0.04x |
| FY Sep 2022 | 0.26x |
| FY Sep 2021 | n/a |
| Jun 2026 | 0.12x |
| Mar 2026 | 0.16x |
| Dec 2025 | 0.16x |
| Sep 2025 | 0.14x |
| Jun 2025 | 0.09x |
| Mar 2025 | 0.03x |
| Dec 2024 | 0.03x |
| Sep 2024 | 0.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity EMBC
| FY Sep 2025 | n/a |
| FY Sep 2024 | n/a |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | +71.1% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+7.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets EMBC
| FY Sep 2025 | +8.0% |
| FY Sep 2024 | +6.3% |
| FY Sep 2023 | +6.1% |
| FY Sep 2022 | +23.9% |
| FY Sep 2021 | +52.6% |
| Jun 2026 | +7.2% |
| Mar 2026 | +10.4% |
| Dec 2025 | +12.6% |
| Sep 2025 | +8.0% |
| Jun 2025 | +6.9% |
| Mar 2025 | +4.6% |
| Dec 2024 | +4.9% |
| Sep 2024 | +6.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+26.5%
operating income after a 30.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital EMBC
| FY Sep 2025 | +37.1% |
| FY Sep 2024 | n/a |
| FY Sep 2023 | +35.3% |
| FY Sep 2022 | +20.9% |
| FY Sep 2021 | +70.7% |
| Jun 2026 | +26.5% |
| Mar 2026 | +39.6% |
| Dec 2025 | +45.4% |
| Sep 2025 | +37.1% |
| Jun 2025 | +35.4% |
| Mar 2025 | +32.6% |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+25.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed EMBC
| FY Sep 2025 | +27.8% |
| FY Sep 2024 | +18.8% |
| FY Sep 2023 | +26.9% |
| FY Sep 2022 | +43.9% |
| FY Sep 2021 | +78.8% |
| Jun 2026 | +25.9% |
| Mar 2026 | +32.7% |
| Dec 2025 | +35.3% |
| Sep 2025 | +27.8% |
| Jun 2025 | +23.8% |
| Mar 2025 | +19.9% |
| Dec 2024 | +17.2% |
| Sep 2024 | +18.8% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
4.63x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing EMBC
| FY Sep 2025 | 8.71x |
| FY Sep 2024 | 10.52x |
| FY Sep 2023 | 12.44x |
| FY Sep 2022 | 7.33x |
| FY Sep 2021 | n/a |
| Jun 2026 | 2.22x |
| Mar 2026 | 4.68x |
| Dec 2025 | 5.03x |
| Sep 2025 | 8.71x |
| Jun 2025 | 6.82x |
| Mar 2025 | 14.33x |
| Dec 2024 | 20.86x |
| Sep 2024 | 10.52x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$1.6B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value EMBC
| FY Sep 2025 | $2.0B |
| FY Sep 2024 | $2.1B |
| FY Sep 2023 | $2.1B |
| FY Sep 2022 | $2.9B |
| FY Sep 2021 | n/a |
| Jun 2026 | $1.4B |
| Mar 2026 | $1.7B |
| Dec 2025 | $1.9B |
| Sep 2025 | $2.0B |
| Jun 2025 | $1.8B |
| Mar 2025 | $2.1B |
| Dec 2024 | $2.5B |
| Sep 2024 | $2.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+42.7%
TTM free cash flow over market value at close 2026-10-26
FCF yield EMBC
| FY Sep 2025 | +22.1% |
| FY Sep 2024 | +2.4% |
| FY Sep 2023 | +4.8% |
| FY Sep 2022 | +23.3% |
| FY Sep 2021 | n/a |
| Jun 2026 | +85.1% |
| Mar 2026 | +39.1% |
| Dec 2025 | +29.6% |
| Sep 2025 | +22.1% |
| Jun 2025 | +23.4% |
| Mar 2025 | +5.4% |
| Dec 2024 | +2.4% |
| Sep 2024 | +2.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.31x
P/E over trailing EPS growth of 4%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing EMBC
| FY Sep 2025 | 0.42x |
| FY Sep 2024 | 0.98x |
| FY Sep 2023 | n/a |
| FY Sep 2022 | n/a |
| FY Sep 2021 | n/a |
| Jun 2026 | 0.63x |
| Mar 2026 | 0.04x |
| Dec 2025 | 0.04x |
| Sep 2025 | 0.42x |
| Jun 2025 | 0.37x |
| Mar 2025 | n/a |
| Dec 2024 | 4.95x |
| Sep 2024 | 0.98x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-09 | 2024-09 | 2023-09 | 2022-09 | |
|---|---|---|---|---|
| Revenue | $1.1B | $1.1B | $1.1B | $1.1B |
| Gross profit | $676.8M | $735.2M | $749.9M | $774.9M |
| Operating income | $242.1M | $166.8M | $221.5M | $309.6M |
| Net income | $95.4M | $78.3M | $70.4M | $223.6M |
| EPS (diluted) | 1.62 | 1.34 | 1.22 | 3.89 |
| Operating cash flow | $191.7M | $35.7M | $67.7M | $412.2M |
| Cash | $225.5M | $267.5M | $326.3M | $330.9M |
| Long-term debt | $1.4B | $1.6B | $1.6B | $1.6B |
| Dividends paid | $35.0M | $34.5M | $34.4M | $8.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
EMBC Stock Sonar score 6/7 axes
Find similar shapesCompareEMBC ranks highest on profitability (90th percentile) and insider conviction (89th), and lowest on growth (18th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EMBC filings, in plain words
Are Embecta insiders buying or selling EMBC?
In the 180 days to 2026-10-28, Embecta insiders were net buyers, a net $521.0K: $557.9K of purchases and $37.0K of sales reported on Form 4, by 4 buyers and 1 seller.
Are there planned insider sales of EMBC?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $36.9K of stock; the latest, by Morris Milton Mayo, was filed 2026-09-04.
Read the full summary
In the 180 days to 2026-10-28, Embecta insiders were net buyers of EMBC, a net $521.0K across purchases and sales reported on Form 4 by 4 buyers and 1 seller. Purchases outweighed sales more than tenfold by value. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $36.9K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
